82 / 1631
Endpoint
Assumptions
Source of data
Disease recurrence
-Mean dose is assumed to be predictive of disease control.
- HR for 0 vs 20 Gy and HR for 20 vs 30 Gy from randomized trials.
-A linear interpolation of the HR is performed for mean doses between 0,20 and 30 Gy.
- Doses above 30 Gy assumed not to give benefit
Herbst C et al. Haematologica
2010;95:494–500
Engert A et al. N Engl J Med
2010;363:6430-5
Eich HT et al. J Clin Oncol
2010;28:4199–206.
Cardiac related
mortality
- Mean dose to heart is assumed predictor of developing
- Linear ERR: 7.4 %/Gy (male) 7.2%/Gy (female)
- Background mortality as function of age from cdc data
Nimwegen et al 2016
Second breast cancer
- Mean dose to breast is assumed predictor of developing
- ERR=14.9%/Gy
- Assumed risk of dying after developing: 10.3% (SEER)
Second lung cancer
- Mean lung dose is assumed predictor
- ERR=14.1%/Gy
- Background risk separate for men and women (SEER)
- Assumed risk of dying after developing: 82.3% (SEER)
Travis et al 2002
Dose effect relationships from clinical data